Advertisement

Topics

Cholesterol Efflux Capacity and Atherosclerosis.

06:00 EDT 15th April 2011 | BioPortfolio

Summary of "Cholesterol Efflux Capacity and Atherosclerosis."

To the Editor: Khera et al. (Jan. 13 issue)(1) report that cholesterol efflux from macrophages was a marginally better predictor of coronary artery disease than high-density lipoprotein (HDL) cholesterol (odds ratio, 0.75 vs. 0.85). They feel that the heterogeneity in particle size, charge, and protein composition of HDL make HDL cholesterol levels a poor surrogate for cholesterol efflux capacity and reduce the predictive value of HDL cholesterol for carotid intima-media thickness and coronary artery disease. Of all the HDL particles, HDL(2) plasma levels have shown the greatest hazard reduction for incident coronary heart disease.(2) Furthermore, macrophage cholesterol efflux positively . . .

Affiliation

Journal Details

This article was published in the following journal.

Name: The New England journal of medicine
ISSN: 1533-4406
Pages: 1472-1475

Links

DeepDyve research library

PubMed Articles [5650 Associated PubMed Articles listed on BioPortfolio]

Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.

We investigated relationships between statin and niacin/statin combination therapy and the concentration of high-density lipoprotein particles (HDL-P) and cholesterol efflux capacity, 2 HDL metrics th...

Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease.

Serum lipoproteins influence cell cholesterol content by delivering and removing cholesterol to/from cells, functions mainly exerted by LDL and HDL, respectively. Especially in the case of HDL, struct...

Lomitapide affects HDL composition and function.

Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated ...

Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.

Recent genome-wide association studies have revealed that variations near the gene locus encoding the transcription factor Krüppel-like factor 14 (KLF14) are strongly associated with HDL cholesterol ...

Role of the ABC transporters A1 and G1, key reverse cholesterol transport proteins, in atherosclerosis.

Atherosclerosis is one of the most common causes of death worldwide. Epidemiology studies firmly established an inverse relationship between atherogenesis and distorted lipid metabolism, in particular...

Clinical Trials [1871 Associated Clinical Trials listed on BioPortfolio]

Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting s...

Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

This is a prospective, placebo-controlled, cross-over trial comparing the the effects of approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on several ...

Epidemiology of Plasma Fatty Acids and Atherosclerosis

To measure by gas-liquid chromatography the relative concentrations of all saturated and unsaturated fatty acids found in the cholesterol ester and phospholipid fractions of plasma from 4,...

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Homozygous familial hypercholesterolemia is a rare inherited disease of metabolism. It occurs in less than 1 in 1 million people within the United States. Patients with the disease are t...

Characterizing PAI-1 Modulation on Monocyte Adhesion

To determine how altering the expression of a gene known as PAI-1 may affect the adhesive capacity of cells that play a critical role in the developement of human atherosclerosis.

Medical and Biotech [MESH] Definitions

Fatty acid esters of cholesterol which constitute about two-thirds of the cholesterol in the plasma. The accumulation of cholesterol esters in the arterial intima is a characteristic feature of atherosclerosis.

The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.

Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.

Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.

A fluorescent probe with low toxicity which is a potent substrate for P-glycoprotein and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of P-glycoprotein in both normal and malignant cells. (Leukemia 1997;11(7):1124-30)

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topic

Cholesterol
Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...


Searches Linking to this Article